Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209845 · ClinicalTrials.gov registry record · Phase 1
Ketamine for Low Mood States in the ER
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01209845: Completed Phase 1 study, sponsored by Yale University.
NCT01209845 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209845, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The investigators hope to see if a commonly used drug such as ketamine could help depressed ER patients feel better and improve their mood quickly.
Primary Outcome
The MADRS measures mood (depression) and item 10 measures suicide ideation.
Interventions
- DRUG ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT01209845 record still lists
NCT01209845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which ketamine is the first listed.
NCT01209845 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01209845 about?
NCT01209845 is a clinical study titled "Ketamine for Low Mood States in the ER". The investigators hope to see if a commonly used drug such as ketamine could help depressed ER patients feel better and improve their mood quickly.
What is the current status of trial NCT01209845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01209845?
The interventions under investigation include: ketamine (DRUG).
Who is sponsoring clinical trial NCT01209845?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01209845's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia